Aptalis Pharmaceutical Technologies is now Adare Pharmaceuticals

May 5, 2015

 On April 1, 2015, Aptalis Pharmaceutical Technologies was divested from Actavis plc (NYSE: ACT) to TPG, a global private investment firm. The company’s new name is Adare Pharmaceuticals. Adare Pharmaceuticals provides enhanced medicines, creating new possibilities for improved patient health. 

 

On April 1, 2015, Aptalis Pharmaceutical Technologies was divested from Actavis plc (NYSE: ACT) to TPG, a global private investment firm. The company’s new name is Adare Pharmaceuticals.

 

Adare Pharmaceuticals provides enhanced medicines, creating new possibilities for improved patient health.

 

Building upon our legacy, we strive to reshape medicines tailored to the needs of the evolving global healthcare market. Through internal development and the acquisition of new technologies and products, we will expand our pipeline and capabilities to deliver greater value to partners and patients.

 

For decades, we have solved complex formulation, manufacturing and commercialization challenges, resulting in transformational medicines that deliver value to all our stakeholders.

 

We see opportunities for transforming medicines where others cannot because of our proprietary technologies, as well as our employees’ expertise and experience in R&D, manufacturing complex products and commercialization.

 

More than ever before, we have the vision, resources and talent, making the company uniquely suited to unlock the potential of more medicines, helping patients to maximize the benefit of their treatments.

 

For more information, contact Lisa.Miller@adarepharma.com or visit www.AdarePharma.com

 

©2015 Adare Pharmaceuticals, Inc.